Related Experiment Video

Updated: Aug 6, 2026

Multicellular Human Alveolar Model Composed of Epithelial Cells and Primary Immune Cells for Hazard Assessment
09:27

Multicellular Human Alveolar Model Composed of Epithelial Cells and Primary Immune Cells for Hazard Assessment

Published on: May 6, 2020

Considerations for hepatitis B as part of a combination vaccine

D P Greenberg1

  • 1Center for Vaccine Research, Children's Hospital of Pittsburgh, PA 15213-2583, USA. greenbd@chplink.chp.edu

The Pediatric Infectious Disease Journal
|November 13, 2001
PubMed

Insights

Combination vaccines simplify infant immunization schedules. Hepatitis B vaccine (HepB) in combination vaccines given at 2, 4, and 6 months is safe and effective, improving vaccine coverage.

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Background:

  • The US strategy to eliminate hepatitis B virus (HBV) transmission includes infant immunization.
  • Increasing childhood vaccine recommendations necessitates simplified schedules and combination vaccines for improved coverage.

Purpose of the Study:

  • To review considerations for including hepatitis B virus vaccine (HepB) in combination vaccines.
  • To assess the safety and immunogenicity of HepB-containing combination vaccines.

Main Methods:

  • Literature review on incorporating HepB into combination vaccines.
  • Analysis of clinical studies on HepB administration schedules and vaccine responses.

Main Results:

  • A combination vaccine with HepB and other infant antigens is available for 2, 4, and 6-month administration.
  • HepB in combination vaccines at 2, 4, 6 months elicits similar seroprotective responses to the 0, 1, 6-month schedule.
  • Combination vaccines show similar or fewer adverse reactions compared to separate vaccine administration.
  • An additional HepB dose from combination vaccines (total of four) did not increase adverse reactions.

Conclusions:

  • HepB-containing combination vaccines administered at 2, 4, and 6 months are safe and immunogenic.
  • These combination vaccines simplify the childhood immunization schedule, aiding in disease prevention.
Abstract

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...